JPRN-UMIN000039803招募中未知
Special Drug Use Surveillance of Alecensa Capsules in Pediatric Patients- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphoma - - Special Drug Use Surveillance of Alecensa Capsules in Pediatric Patients- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 15years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •>14 years old at Alecensa initiation
研究者
相似试验
已完成
不适用
ALECENSA Drug Use Surveillanceung CancerJPRN-UMIN000014989Chugai Pharmaceutical Co. Ltd.1,000
招募中
不适用
Special Drug Use Surveillance of Rozlytrek Capsule in Pediatric Patients - Advanced or recurrent solid tumors with NTRK gene fusionsAdvanced or recurrent solid tumors with NTRK gene fusionsJPRN-UMIN000039670Chugai Pharmaceutical Co. Ltd.10
已完成
不适用
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or refractory CD30-positive peripheral T cell lymphoma or Pediatric Hodgkin LymphomaPeripheral T cell lymphoma and Pediatric Hodgkin lymphomaJPRN-jRCT1080224999Takeda Pharmaceutical Company Limited95
招募中
Unknown
Post-marketing Surveillance Protocol Number;CLCZ696A1402HypertensionJPRN-jRCT2031230283Sugigmoto Toshiya1,000
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660